Novo Nordisk plans to submit weekly growth hormone for approval in H1

Novo Nordisk and Ascendis Pharma could soon face each other on the market for treating children with growth hormone deficiency, as the Danish pharmaceutical giant is intending to file its candidate for approval in the US where latter company is already present.

Photo: Kevin Grønnemann

Novo Nordisk is planning to submit its once-weekly growth hormone deficiency (GHD) treatment for children, Sogroya, for regulatory approval in the first half of 2022, the company announces in its financial report on Wednesday.

This comes after the completion of a phase III study in December of last year, in which Sogroya was compared with Novo’s other hormone treatment, Norditropin, which is administered daily. Norditropin was approved by the US Drug and Food Administration (FDA) in 2000.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs